Display options
Cite
Watanabe N, Bajgain P, Sukumaran S, et al. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016;5(12):e1253656doi: 10.1080/2162402X.2016.1253656.
Watanabe, N., Bajgain, P., Sukumaran, S., Ansari, S., Heslop, H. E., Rooney, C. M., Brenner, M. K., Leen, A. M., & Vera, J. F. (2016). Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology, 5(12), e1253656. https://doi.org/10.1080/2162402X.2016.1253656
Watanabe, Norihiro, et al. "Fine-tuning the CAR spacer improves T-cell potency." Oncoimmunology vol. 5,12 (2016): e1253656. doi: https://doi.org/10.1080/2162402X.2016.1253656
Watanabe N, Bajgain P, Sukumaran S, Ansari S, Heslop HE, Rooney CM, Brenner MK, Leen AM, Vera JF. Fine-tuning the CAR spacer improves T-cell potency. Oncoimmunology. 2016 Nov 08;5(12):e1253656. doi: 10.1080/2162402X.2016.1253656. eCollection 2016. PMID: 28180032; PMCID: PMC5214260.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2016 Nov 08;5(12):e1253656. doi: 10.1080/2162402X.2016.1253656. eCollection 2016.

Fine-tuning the CAR spacer improves T-cell potency.

Oncoimmunology

Norihiro Watanabe, Pradip Bajgain, Sujita Sukumaran, Salma Ansari, Helen E Heslop, Cliona M Rooney, Malcolm K Brenner, Ann M Leen, Juan F Vera

Affiliations

  1. Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children's Hospital, and Houston Methodist Hospital , Houston, Texas, USA.

PMID: 28180032 PMCID: PMC5214260 DOI: 10.1080/2162402X.2016.1253656

Abstract

The adoptive transfer of genetically engineered T cells expressing chimeric antigen receptors (CARs) has emerged as a transformative cancer therapy with curative potential, precipitating a wave of preclinical and clinical studies in academic centers and the private sector. Indeed, significant effort has been devoted to improving clinical benefit by incorporating accessory genes/CAR endodomains designed to enhance cellular migration, promote

Keywords: CAR T cell; T cells

References

  1. Immunol Rev. 2014 Jan;257(1):127-44 - PubMed
  2. Cancer Res. 2015 Jan 15;75(2):296-305 - PubMed
  3. Cancer Res. 2009 May 1;69(9):4010-7 - PubMed
  4. N Engl J Med. 2014 Oct 16;371(16):1507-17 - PubMed
  5. Mol Ther. 2014 Jun;22(6):1211-20 - PubMed
  6. Blood. 2011 Nov 3;118(18):4817-28 - PubMed
  7. J Immunol. 2008 Apr 1;180(7):4901-9 - PubMed
  8. Gene Ther. 2010 Oct;17(10):1206-13 - PubMed
  9. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1735-40 - PubMed
  10. J Clin Invest. 2008 Jan;118(1):294-305 - PubMed
  11. J Exp Med. 2005 Jan 3;201(1):139-48 - PubMed
  12. J Immunother. 2005 May-Jun;28(3):203-11 - PubMed
  13. Cancer Immunol Res. 2015 Feb;3(2):125-35 - PubMed
  14. Gene Ther. 1995 Oct;2(8):539-46 - PubMed
  15. Immunol Rev. 2014 Jan;257(1):107-26 - PubMed
  16. Clin Cancer Res. 2013 Jun 15;19(12):3153-64 - PubMed
  17. Mol Ther. 2015 Apr;23(4):757-68 - PubMed
  18. Blood. 2009 Apr 16;113(16):3716-25 - PubMed
  19. Crit Rev Oncog. 2014;19(1-2):121-32 - PubMed
  20. Mol Ther. 2014 Mar;22(3):623-33 - PubMed
  21. Mol Ther. 2009 May;17(5):880-8 - PubMed
  22. Front Immunol. 2012 Feb 20;3:16 - PubMed
  23. Handb Exp Pharmacol. 2008;(181):329-42 - PubMed
  24. Blood. 2005 Jul 1;106(1):376-83 - PubMed
  25. J Immunol. 2012 Oct 1;189(7):3430-8 - PubMed
  26. Blood. 2011 Feb 10;117(6):1888-98 - PubMed
  27. Blood. 2013 Jan 24;121(4):573-84 - PubMed
  28. Cancer Immunol Res. 2015 Apr;3(4):368-79 - PubMed
  29. Blood. 2014 Jun 12;123(24):3750-9 - PubMed
  30. Gene Ther. 2000 Jun;7(12):1067-75 - PubMed
  31. J Exp Med. 2010 Mar 15;207(3):651-67 - PubMed
  32. Leukemia. 2016 Feb;30(2):492-500 - PubMed
  33. Nat Rev Immunol. 2010 May;10(5):328-43 - PubMed
  34. Nat Med. 2011 Sep 18;17(10):1290-7 - PubMed
  35. Blood. 2013 Feb 14;121(7):1165-74 - PubMed
  36. J Clin Invest. 2016 Jun 1;126(6):2123-38 - PubMed
  37. J Vis Exp. 2010 Sep 26;(43):null - PubMed
  38. Gene Ther. 2015 May;22(5):391-403 - PubMed

Publication Types

Grant support